NATH BIOGENES (INDIA)
|
NATH BIOGENES (INDIA) Last 5 Year Financial Ratios History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2013 | Mar2012 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 20.85 | 18.43 | -35.46 | 7.34 | 5.75 |
CEPS(Rs) | 22.56 | 20.01 | -33.84 | 10.16 | 8.69 |
DPS(Rs) | 2.00 | 2.00 | 2.00 | - | - |
Book NAV/Share(Rs) | 320.94 | 301.61 | 285.16 | 35.91 | 28.57 |
Tax Rate(%) | 4.68 | 3.19 | -6.23 | 4.48 | -1.38 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 15.02 | 16.25 | 13.37 | 14.45 | 11.84 |
EBIT Margin(%) | 15.26 | 15.44 | -18.96 | 11.60 | 8.78 |
Pre Tax Margin(%) | 12.50 | 12.00 | -22.79 | 8.93 | 7.32 |
PAT Margin (%) | 11.91 | 11.62 | -24.21 | 8.53 | 7.42 |
Cash Profit Margin (%) | 12.89 | 12.62 | -23.10 | 11.80 | 11.22 |
Performance Ratios | |||||
ROA(%) | 4.74 | 4.57 | -15.03 | 8.50 | 7.73 |
ROE(%) | 6.70 | 6.28 | -22.48 | 22.76 | 20.12 |
ROCE(%) | 7.26 | 7.09 | -14.84 | 23.88 | 19.09 |
Asset Turnover(x) | 0.40 | 0.39 | 0.62 | 1.00 | 1.04 |
Sales/Fixed Asset(x) | 1.22 | 1.12 | 1.62 | 2.08 | 2.22 |
Working Capital/Sales(x) | 1.08 | 0.99 | 1.02 | 6.37 | 5.12 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.82 | 0.89 | 0.62 | 0.48 | 0.45 |
Receivable days | 105.14 | 110.74 | 69.85 | 44.32 | 36.68 |
Inventory Days | 240.40 | 259.30 | 195.06 | 189.43 | 193.69 |
Payable days | -1,457.17 | 744.29 | 1,503.38 | -4,219.16 | 1,576.65 |
Valuation Parameters | |||||
PER(x) | 8.33 | 7.69 | - | - | - |
PCE(x) | 7.70 | 7.08 | -6.31 | - | - |
Price/Book(x) | 0.54 | 0.47 | 0.75 | - | - |
Yield(%) | 1.15 | 1.41 | 0.94 | - | - |
EV/Net Sales(x) | 1.09 | 1.12 | 1.78 | 0.24 | 0.19 |
EV/Core EBITDA(x) | 7.18 | 6.79 | 12.65 | 1.60 | 1.54 |
EV/EBIT(x) | 7.15 | 7.23 | -9.36 | 2.05 | 2.20 |
EV/CE(x) | 0.50 | 0.50 | 0.78 | 0.21 | 0.20 |
M Cap / Sales | 0.99 | 0.89 | 1.46 | - | - |
Growth Ratio | |||||
Net Sales Growth(%) | 10.37 | 8.26 | 102.15 | 11.13 | - |
Core EBITDA Growth(%) | 2.11 | 26.77 | 90.81 | 31.43 | - |
EBIT Growth(%) | 9.13 | 188.13 | -430.58 | 46.76 | - |
PAT Growth(%) | 13.16 | 151.96 | -673.70 | 27.66 | - |
EPS Growth(%) | 13.11 | 151.98 | -583.10 | 27.66 | - |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.18 | 0.18 | 0.17 | 0.33 | 0.25 |
Current Ratio(x) | 2.18 | 2.40 | 2.41 | 1.22 | 1.34 |
Quick Ratio(x) | 1.30 | 1.44 | 1.27 | 0.43 | 0.42 |
Interest Cover(x) | 5.52 | 4.49 | -4.96 | 4.35 | 6.02 |
Total Debt/Mcap(x) | 0.33 | 0.39 | 0.23 | - | - |
Compare Financial Ratios of peers of NATH BIOGENES (INDIA)
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
NATH BIOGENES (INDIA) | ₹346.1 Cr | 3.8% | -5.1% | -11.5% | Stock Analytics | |
BOMBAY BURMAH TRADING CORPORATION | ₹17,556.0 Cr | -1.8% | -10% | 72% | Stock Analytics | |
KAVERI SEED COMPANY | ₹4,564.2 Cr | 6.1% | 4.7% | 42.6% | Stock Analytics | |
VENKYS (INDIA) | ₹2,399.5 Cr | -1% | 0.7% | -14.7% | Stock Analytics | |
BOMBAY SUPER HYBRID SEEDS | ₹1,518.8 Cr | -2.3% | -10.8% | -36.8% | Stock Analytics | |
TIERRA AGROTECH | ₹402.6 Cr | 2.3% | 1.4% | -34.8% | Stock Analytics |
NATH BIOGENES (INDIA) Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
NATH BIOGENES (INDIA) | 3.8% |
-5.1% |
-11.5% |
SENSEX | 3.5% |
-0.1% |
21.9% |
You may also like the below Video Courses